The company provides more than 1,5 ready-to-use antibodies and concentrated antibodies for diagnosis and research, a full range of immunology and molecular pathology reagents, and also acts as an agent for thousands of imported antibodies and supporting reagents. Maixin Company is the sole agent of the automatic immunohistochemical staining system of Labvision Company in Chinese mainland, and provides all-round technical support and services.
In the past ten years, Maixin has been adhering to the concept of "professionalism, realism and enterprising", and has always been committed to providing high-quality products that are in sync with the world for the vast number of users, and has established the first immunohistochemical quality control laboratory in China, which has effectively promoted the development of pathology and biology in China. Unique academic marketing, strictly controlled product quality and perfect after-sales service have made Maixin one of the most important suppliers of biomedical reagents in China, and its domestic market share of immunohistochemical reagents has been ranked first for many years.
The full completion of the human genome project marks that we are about to enter a brand-new biological era. Maixin will, as always, provide China scientists with high-quality products and all-round technical support and services, and make its own contribution to human health. In March 1993, Maixin Company was established in Fuzhou Hongshan Science Park with a registered capital of 5, RMB.
In January p>1994, the ready-to-use immunohistochemical antibody was first introduced in China.
In June p>1994, the ready-to-use SP enzyme-labeled kit was first introduced, and its shelf life reached 12 months, reaching the international advanced level.
In April, 1994, the
National Seminar on New Pathology Technology and Progress and the Immunohistochemical Technology Class was held in Fuzhou for the first time in cooperation with the Chinese Pathology Society and the Journal of the Chinese Pathology Society;
In p>1995, Laoxin Company won the honorary title of "Fujian High-tech Enterprise";
In p>1996, Laoxin Company was invited to attend the first national seminar on immunohistochemical standards held in Beijing and made a speech at the conference.
In May p>1997, he initiated and participated in the publication of Diagnostic Immunohistochemistry, the first immunohistochemical diagnostic monograph;
In p>1998, Laoxin Company established its website and registered its domain name in both Chinese and English. At the same time, it also registered two English domain names of "Immunohistochemistry" and "Antibody2", which significantly improved the click-through rate of the company's website.
In p>1999, Maixin trademark was successfully registered by the State Trademark Office and protected by national laws (registration number is 128519);
In September, 2, Chen Mingyi, former secretary of Fujian Provincial Party Committee, Pan Xincheng, vice governor and other provincial and municipal leaders visited Maixin Company and highly affirmed its development.
in p>21, it reached a strategic alliance with LabVision, the largest supplier of immunohistochemical automation instruments in the world;
In p>21, Laoxin Company published the first color immunohistochemical antibody catalogue in the industry, and it has been published continuously to the fifth volume.
In p>22, the National Immunohistochemical Staining Competition sponsored by Maixin Company was held in Wuyishan, Fujian.
in p>23, the company successfully injected capital, with a registered capital of RMB 3.5 million;
In p>23, rabbit monoclonal antibody immunohistochemical reagent was introduced and developed for the first time in China.
In p>23, General Manager Wang Xiaoya of the old new company led the heads of relevant departments of the company to visit the United States and formed a strategic alliance with LabVision.
In p>23, Laoxin Company wholly funded the inaugural meeting of CCP (China Pathologist Working Committee) held in Hainan.
In p>25, in cooperation with foreign laboratories, a polymer-based non-biotin immunohistochemical enzyme-labeled amplification system was successfully developed.
In p>26, it won the free subsidy from the Innovation Fund for Small and Medium-sized Enterprises of the Ministry of Science and Technology, and the prostate double-staining three-label detection kit was highly praised by experts.
In August p>26, the "Pathology Forum at Home and Abroad" sponsored by Maixin Company was held in Fuzhou.
In p>27, the high amplification and high sensitivity immunohistochemical amplification system Max7, which was created by Laoxin Company, was successfully developed.
In p>27, the first color immunohistochemical monograph "Immunohistochemical Pathological Diagnosis" in China was published under the sole sponsorship of Maixin Company.
In p>27, the purification laboratory of Laoxin Company was completed, and the GMP transformation system successfully passed the certification of Fujian Food and Drug Administration.
In July, 27, thirteen immunohistochemical kits of Maixin Company passed the test of China Institute for Identification of Pharmaceutical and Biological Products for the first time in China.
in November p>27, the company successfully increased its capital again, with a registered capital of RMB 2 million;
In p>28, the five-year national immunohistochemical quality control activity supported by Maixin Company was successfully completed.
In p>29, the trademark of Laoxin Company was awarded as "Famous Trademark in Fujian Province", and in the same year, the company won the honorary title of "High-tech Enterprise in Fujian Province" again.
In p>29, the special pathology fund "Maixin Pathology" was established for the first time in China, which funded scientific and technical personnel to conduct in-depth research, standardization and popularization of immunohistochemistry;
in p>29, the company successfully increased its capital again, with a registered capital of RMB 3 million.